Aktis Oncology, Inc. (AKTS)
NASDAQ:AKTS
AKTS Stock Chart & Stats
$20.25
--
Market closed
$20.25
--
Day’s Range― - ―
52-Week Range$14.72 - $29.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.08B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,404,617
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.50Price Target Upside70.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aktis Oncology, Inc. News
AKTS FAQ
What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $29.16 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $1.08B.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aktis Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,404,617 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Currently, no hedge funds are holding shares in AKTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aktis Oncology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
AKTS Stock 12 Month Forecast
Average Price Target
$34.50
▲(70.37% Upside)
Ownership Overview
47.63% Insiders
44.02% Other Institutional Investors
4.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---